The somatically acquired V600E mutation of the BRAF gene has been recently described as a molecular marker of hairy cell leukemia (HCL). We developed an allele-specific PCR for this mutation, and studied 62 patients with HCL, one with HCL variant, 91 with splenic marginal zone lymphoma, 29 with Waldenström macroglobulinemia, and 57 with B-cell chronic lymphoproliferative disorders. The BRAF V600E mutation was detected in all HCL cases, and in only two of the remaining 178 patients. These two subjects had a B-cell chronic lymphoproliferative disorders that did not fulfill the diagnostic criteria for HCL. Despite the PCR positivity, the mutation could not be detected by Sanger sequencing in these two cases, suggesting that it was associated with a small subclone. We conclude that the BRAF V600E mutation is present in all HCL patients and that, in combination with clinical and morphological features, represents a reliable molecular marker for this condition.
Introduction
Hairy cell leukemia (HCL) is a distinct lymphoid neoplasm characterized by splenomegaly and peripheral cytopenias. [1] [2] [3] [4] Recently, Tiacci et al 5 The above observation is of paramount importance for a clear-cut diagnosis of HCL, and also for its differential diagnosis from HCL-mimicking diseases such as splenic marginal zone lymphoma (SMZL), 6, 7 splenic lymphoma/leukemia undifferentiated, 8 and B cell chronic lymphoproliferative disorders (B-CLPD).
9,10
The aim of this study was to define the incidence of the BRAF V600E mutation in a large series of diverse lymphoid disorders. To this aim, we developed an allelespecific PCR for this mutation and studied a series of 240 mature B-cell lymphoid neoplasms, including 62 HCL cases. The amplification product was separated on 3% agarose gel and visualized by SYBR safe staining (Invitrogen, Inc., Carlsbad, CA, USA). The PCR products were purified and sequenced using BigDye® Terminator v3.1 Cycle Sequencing Kit and an ABI 3500 automatic sequencer (Applied Biosystems, Foster City, CA, USA). Healthy donors were used as negative controls.
Allele Specific Oligonucleotides (ASO)-PCR assays
Two different forward primers with substitution of a single base at the end of the primer (FW5'-TAGGTGATTTTGGTCTAGCTACCGT-3' and FM 5'-TAGGTGATTTTGGTCTAGCTACCGA-3') were designed to amplify the wild-type allele or BRAF T1860A transversion mutation respectively. To prevent the amplification of the nonmatching primer, an additional nucleotide mismatch (A >C) located 3 bases from the 3' termini of the allele-specific primers was incorporated.
The sequence of the reverse primer was the same as used before. Mutated or wildtype sequences from PB or BM samples were specifically amplified in a noncompetitive PCR as described before. BM biopsies were amplified in a final 
Results and Discussion
Clinical features of the HCL patients studied are reported in the Supplemental Table   S1 . The BRAF V600E mutation was found in all the 62 HCL cases studied. In 61 cases, DNA derived from BM biopsies with a hairy cell infiltration ranging from 15% to 95%, while in the remaining one it derived from PB with 2% of hairy cells detected by flow cytometry immunophenotyping. Sanger sequencing in patients with heavily infiltrated BM showed an heterozygous pattern for the mutation. Detailed description of HCL samples is reported in the Supplemental Table S2 .
The BRAF V600E mutation was absent in the HCL-V case, and in patients with SMZL or WM. Two patients with B-CLPD showed a weak positivity in the BM ( Figure   1 ) by ASO-PCR, but DNA Sanger sequencing did not reveal the mutation in these cases. Histological and flow cytometry features of these 2 cases are summarized in Table 1 . The BRAF V600E mutation has been previously found in a significant proportion of solid cancers [12] [13] [14] and in Langerhans cell histiocytosis, 15 while BRAF mutations other than V600E have been observed in small proportions of patients with ALL 16, 17 or Bcell lymphomas. 18 The findings of this study indicate that the allele-specific PCR we developed is able to detect the BRAF V600E mutation in all patients with HCL. The same results have been recently obtained using another PCR approach, 19 or high-resolution melting analysis. 20 The fact that we successfully analyzed DNA extracted from BM biopsies is of crucial importance, as this most often represents the only available material containing hairy cells in HCL patients.
Within diverse mature B-cell neoplasms, the BRAF V600E mutation was highly specific for HCL. In fact, the allele-specific PCR was positive in only two out of 57 patients with B-CLPD, who did not fulfill the diagnostic criteria for HCL. Despite the PCR positivity, the mutation could not be detected by Sanger sequencing, suggesting that it was associated with a small subclone. The two patients had different features, and no conclusion can be drawn at present concerning the prevalence of BRAF V600E-positive clones in B-CLPD.
We conclude that the BRAF V600E mutation is present in all HCL patients and that, in combination with clinical and morphological features, represents a reliable molecular maker for the laboratory diagnosis this mature B-cell neoplasm. (Table 1) , the only similarity between this case and HCL was the expression of cyclin D1/bcl1
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oncoprotein (streptavidin-biotic-peroxidase complex method/SABC, DAB chromogen, 40x). Panel E: While ANXA-1, the most specific marker of HCL, was negative on the lymphoid population, and only expressed by myeloid precursors, which serve as internal control (SABC, DAB chromogen, 60x).
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